Pfizer
Eileen Cheigh is currently the VP of Business Assessment for the Chief Business Innovation Office at Pfizer. Eileen has been with Pfizer since August 1996 and in their current role since February 2014. Prior to their current role, they were the Senior Director of Global Strategy & Operations for the Established Products Business Unit where they oversaw the development and implementation of Pfizer's global generics expansion strategy. This included prioritizing investments across markets, project management of organic and inorganic portfolio expansion, and governance model. Under their leadership, the Established Products Business Unit met global financial targets of $1.2B in 2013 revenues and 41% growth through 2015.
Before joining Pfizer, Eileen held various roles in sales and underwriting for health insurance plans at Aetna from January 1991 to December 1994. In their role as a Sales Analyst / Insurance Underwriter, they were responsible for creating new business proposals and implementation plans for large employer health plans in very competitive West Coast health care benefits markets. Eileen also conducted research, risk assessment, and financial analysis in underwriting new policies.
Eileen Cheigh has an MBA in Health Care Management and Finance from The Wharton School and a BA in Economics and American Studies from Wesleyan University.
This person is not in any teams
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.